The implantation of the double intraocular lens (IOL) system (IOL-VIP) can improve best corrected visual acuity (BCVA) in patients with low vision due to advanced maculopathy, according to a report published in the September issue of the Journal of Cataract and Refractive Surgery.
The implantation of the double intraocular lens (IOL) system (IOL-VIP) can improve best corrected visual acuity (BCVA) in patients with low vision due to advanced maculopathy, according to a report published in the September issue of the Journal of Cataract and Refractive Surgery.
Luis Amselem from the Hospital General Universitario, Valencia, Spain and colleagues evaluated the efficacy of a standard double IOP system in patients with low vision and central scotoma due to macular degeneration. The interventional, prospective, non-comparative case series included 13 consecutive surgical procedures in 10 patients.
At 12-months follow-up the difference between pre- and postoperative BCVA, refraction, position of IOLs, endothelial cell density and occurrences of postoperative complications were evaluated.
At 12-months, mean BCVA was 0.68 logMAR compared with 1.37 logMAR preoperatively. Mean best corrected clinical gain was 44%.
No statistically significant difference between the clinically evaluated and theoretically calculated residual refractions was recorded and there were no intraoperative or postoperative complications.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.